Table 1.
Results of nonparametric superposition and noncompartmental analysis performed on mean data for doripenem and doripenem-M-1.
| Continuous venovenous hemofiltration | Continuous venovenous hemodiafiltration | Healthy subjectsa | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Day 1a | Simulated steady-state (day 10) | Day 1a | Simulated steady-state (day 10) | |||||||
| 500 mg q12h |
500 mg q8h |
250 mg q8h |
250 mg q12h |
500 mg q12h |
500 mg q8h |
375 mg q12h |
250 mg q8h |
250 mg q12h |
1000 mg q8h |
|
| Doripenem | ||||||||||
| Cmax,ss (mg/L) | 24.1 | 29.6 | 14.9 | 13.2 | 22.5 | 26.5 | 17.9 | 13.2 | 12.0 | 44.0 |
| AUCτ (mg·h/L) | 97.6 | 114 | 57.1 | 57.1 | 88.4 | 86.5 | 64.9 | 43.3 | 43.3 | 69.6 |
| AUC24,ss (mg·h/L) | N/A | 342.0 | 171.3 | 114.2 | N/A | 259.5 | 129.8 | 129.9 | 86.6 | 208.8 |
| Doripenem-M-1 | ||||||||||
| Cmax,ss (mg/L) | 3.02 | 8.86 | 4.44 | 3.27 | 3.66 | 9.15 | 5.23 | 4.57 | 3.49 | 9.81 |
| AUCτ (mg·h/L) | 24.4 | 58.6 | 29.3 | 29.3 | 21.8 | 54.2 | 40.7 | 27.1 | 27.1 | 21.3 |
| AUC24,ss (mg·h/L) | N/A | 175.8 | 87.9 | 58.6 | N/A | 162.6 | 81.4 | 81.3 | 54.2 | 63.9 |
AUC24,ss: total daily area under the curve at steady state; AUCτ: area under the curve at steady state during the dosing interval τ; Cmax,ss: maximum plasma concentration at steady state; q8h: every 8 hours; q12h: every 12 hours.
aThe day 1 500 mg q12h CRRT data and the healthy subject data are observed results from single- and multiple dose studies. All doripenem dosing regimens were a 1-hour infusion duration.